Skip to content

特鲁利夫大麻

US · TRLV #2769 按市值排名 上市于 1970
11.56 +0.66 +6.06%
定时行情快照,非实时行情。 · 2026-11-06 20:02

估值 各估值倍数与自身5年区间的对比

市净率 2.58 高于历史水平 第82百分位
5年平均 1.57 · 在Drug Manufacturers - Specialty & Generic中排名第45/70
市盈率 -4.16 处于历史正常水平 第47百分位
5年平均 1.21 · 前瞻 27.46
市销率 1.74 处于历史正常水平 第57百分位
5年平均 1.90 · 前瞻 2.16 · 在Drug Manufacturers - Specialty & Generic中排名第30/80

同业对比 Drug Manufacturers - Specialty & Generic

公司 市值 市盈率(TTM) 市净率 股息率
特鲁利夫大麻 (TRLV) 2.23B -5.00 2.89 0.00%
Takeda Pharmaceutical (TAK) 67.36B 296.06 1.43 1.49%
Teva Pharmaceutical Industries (TEVA) 49.72B 99.09 6.23 0.00%
Haleon (HLN) 40.17B 18.77 1.82 2.08%
Zoetis (ZTS) 32.26B 13.39 9.77 2.63%
United Therapeutics (UTHR) 23.94B 21.22 3.81 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★★☆ 合理价值12.52 经济护城河None 不确定性High

当前股价低于晨星合理价值估算8.3%。

合理价值

Trulieve Cannabis Corp receives a 4-star quantitative star rating, indicating our belief that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 18% discount to our quantitative fair value estimate of $12.52 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's balance sheet increases our fair value estimate. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. Reflecting the firm's leverage is its EBITDA/interest coverage ratio of -2.0, which lies in the bottom 20% compared with global peers. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be undervalued.

On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 1.2%, for example, falls in the bottom 40% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

经济护城河

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-11-06 20:02:21 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

特鲁利夫大麻 讨论区 0 条评论

发表评论